Venlo, The Netherlands, January 31, 2018 – QIAGEN N.V. announces that its Managing Board, upon authorization of the Supervisory Board, has passed a resolution to exercise the authorization granted by the General Meeting of Shareholders on June 21, 2017, and to purchase shares in the Company up to a total of US$200 million (or the equivalent Euro amount thereof, in each case excluding transaction costs). Based on the closing price on January 30, 2018, this represents a repurchase volume of approximately 5.9 million shares. The repurchase program is scheduled to begin at the earliest on February 6, 2018, and to be completed on December 21, 2018, at the latest, or if the upcoming General Meeting of Shareholders will extend the authorization to repurchase shares, on June 30, 2019, at the latest. Details of the repurchase program will be announced before its actual commencement in line with Article 5 Section (1) and (6) of the EU regulation 596/2014 in conjunction with the regulatory technical standards adopted by the European Commission (so called Safe Harbour Regulation). Repurchased shares will be held in treasury in order to satisfy obligations from employee share-based remuneration plans.
QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
The Netherlands
ISIN: NL0012169213
Frankfurt Stock Exchange, Regulated Market (Prime Standard)
Contacts QIAGEN N.V.:
Corporate Communications
John Gilardi, Tel: +49 2103 29 11711; ir@qiagen.com
Thomas Theuringer, Tel: +49 2013 29 11826 pr@qiagen.com